Compare Cassava Sciences Inc (FLNA) vs ProShares Ultra Semiconductors (USD) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

USD stock is trading at $94.84, down 7.72% over the past 24 hours, with technical indicators showing a bullish overall signal despite the recent decline. The stock maintains strong moving average support with 9 buy signals versus 4 sell signals, while oscillators remain neutral. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Support levels are established at $93, $91, and $87, with resistance at $97, $100, and $104.

The stock's technical strength suggests potential recovery from current levels, though fundamental data remains limited. The bullish moving average configuration and upcoming dividend provide near-term catalysts, while the neutral RSI indicates room for movement. Key risks include market volatility and the need for clearer fundamental metrics to support current valuation levels.